Oragenics, Inc.
OGENHealthcare|Biotechnology|US
$0.35
+0.00 (+0.04%)
DCF Value
$1.56
Tangible Book / Share
$0.83
Cash / Share
$0.87
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03234465 Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day | Oral Mucositis | P2 | Terminated | 200 | RCT, Double-blind | AG013 |
| NCT06870240 A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury | Mild Traumatic Brain Injury, Concussion | P2 | Not Yet Recruiting | 40 | Double-blind | Neurosteroid enantiomer |
| NCT01520974 Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3) | Oral Health | N/A | Unknown | 48 | RCT, Double-blind | — |